Bilaketaren emaitzak - Eva Muñoz‐Couselo

Findu emaitzak
  1. 1
    Targeting FGFR pathway in breast cancer

    Targeting FGFR pathway in breast cancer nork José Manuel Pérez-García, Eva Muñoz‐Couselo, Jesús Soberino, Fabricio Racca, Javier Cortés

    Argitaratua 2017
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    <em>NRAS</em>-mutant melanoma: current challenges and future prospect

    <em>NRAS</em>-mutant melanoma: current challenges and future prospect nork Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, Jesús Soberino-García, José Manuel Pérez-García

    Argitaratua 2017
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?

    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies? nork Mar Riveiro‐Barciela, Eva Muñoz‐Couselo, Jesús Fernández‐Sojo, Nely Díaz‐Mejía, Rafael Parra-López, Marı́a Buti

    Argitaratua 2018
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:
  4. 4
    A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

    A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy nork Adriana Sánchez‐Danés, Jean‐Christophe Larsimont, Mélanie Liagre, Eva Muñoz‐Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, V. del Mármol, Josep Tabernero, Cédric Blanpain

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

    Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 stud... nork Peter Schmid, Roberto Salgado, Y.H. Park, Eva Muñoz‐Couselo, S.B. Kim, Joohyuk Sohn, Seock‐Ah Im, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lei Yin, A. Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi

    Argitaratua 2020
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial nork Brett Hughes, Eva Muñoz‐Couselo, Laurent Mortier, Å. Bratland, Ralf Gutzmer, Osama Roshdy, René González Mendoza, Jacob Schachter, Ana Arance, Florent Grange, Nicolás Meyer, Abhishek Joshi, Salem Billan, P. Zhang, Burak Gümüşçü, Ramona F. Swaby, Jean‐Jacques Grob

    Argitaratua 2021
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab

    Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab nork Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations

    Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti... nork Paolo A. Ascierto, Petri Bono, Shailender Bhatia, Ignacio Melero, Marta Nyakas, Inge Marie Svane, James Larkin, Carlos Gomez‐Roca, Dirk Schadendorf, R. Dummer, Aurélien Marabelle, Christoph Höeller, Mark Maurer, Christopher Harbison, Priyam Mitra, Satyendra Suryawanshi, Kent Thudium, Eva Muñoz‐Couselo

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

    1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-00... nork Célèste Lebbé, Shruthi Ravimohan, Antara Datta, Aparna Chhibber, Eva Muñoz‐Couselo, Caio Guilherme Pereira, Shahneen Sandhu, Ming Zhou, Brendan D. Curti, Nikhil I. Khushalani, Matthew Taylor, Alfonsus Van Den Eertwegh, Ute Hoch, Georgina Long AO, Yull Arriaga, Adi Diab, Helen Gogas

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

    Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of th... nork Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz‐Couselo, Sung‐Bae Kim, Joohyuk Sohn, Seock‐Ah Im, Esther Holgado, Theodoros Foukakis, Sherko Kümmel, Jennifer H. Yearley, Anran Wang, Michael Nebozhyn, Lingkang Huang, Rǎzvan Cristescu, Petar Jelinic, Vassiliki Karantza, Peter Schmid

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL)

    785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) nork Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V. Long, Paolo A. Ascierto, James Larkin, Mario Sznol, Fábio Franke, T. Ciuleanu, Eva Muñoz‐Couselo, A. Perfetti, Célèste Lebbé, Friedegund Meier, Brendan D. Curti, C. Rojas, Hwai‐I Yang, Ming Zhou, Shruthi Ravimohan, Mary Tagliaferri, N. Khushanlani

    Argitaratua 2022
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

    A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-... nork Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel‐Ángel Berciano‐Guerrero, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, Valentina Boni, Lynn M. Schuchter, María González‐Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas Iannotti, Frank J. Hsu, Harriet M. Kluger

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury

    An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury nork Mar Riveiro‐Barciela, Ana Barreira‐Díaz, María‐Teresa Salcedo, Ana Callejo, Eva Muñoz‐Couselo, Patricia Iranzo, Carolina Ortiz, S. Cedrés, Nely Díaz‐Mejía, J. Cobo, Rafael Morales, Juan Aguilar‐Company, Esther Zamora, Mafalda Oliveira, María‐Teresa Sanz‐Martínez, L Viladomiu, Mónica Martínez‐Gallo, Enriqueta Felip, Marı́a Buti

    Argitaratua 2024
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Five latent factors underlie response to immunotherapy

    Five latent factors underlie response to immunotherapy nork Joseph Usset, Axel K.M. Rosendahl Huber, Maria Andrianova, Eduard Batlle, Joan Carles, Edwin Cuppen, Elena Élez, Enriqueta Felip, Marina Gómez-Rey, Deborah Lo Giacco, Francisco Martínez-Jiménez, Eva Muñoz‐Couselo, Lillian L. Siu, Josep Tabernero, Ana Vivancos, Ferran Muiños, Abel González-Pérez, Núria López-Bigas

    Argitaratua 2024
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review

    Adjuvant Therapy Versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multicountry Retrospective Chart Review nork Peter Mohr, Felix Kiecker, Vincent Soriano, O. Dereure, Karmele Mujika, Philippe Saïag, Jochen Utikal, Rama Koneru, Caroline Robert, F. Perez Cuadros, Matías Chacón, Rodrigo U. Villarroel, Yana G. Najjar, Lisa A. Kottschade, Eva Muñoz‐Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu‐Ittu, Maurice Perrinjaquet, Jonathan S. Zager

    Argitaratua 2019
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    2314P Quality and safety of research biopsies (RB) in oncology clinical trials

    2314P Quality and safety of research biopsies (RB) in oncology clinical trials nork Paolo Nucíforo, Fiorella Ruíz‐Pace, J. Jiménez, Raquel Comas, R. Fasani, Cristina Viaplana, C. Sevillano, Pablo Martínez, X Serres i Créixams, C. Saura Manich, M.E. Elez Fernandez, Ana Oaknin, Irene Braña, Eva Muñoz‐Couselo, Teresa Macarulla, J. Carles Galceran, Josep Tabernero, Enriqueta Felip, Elena Garralda, Rodrigo Dienstmann

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE</scp>‐119

    Contribution of tumour and immune cells to <scp>PD‐L1</scp> expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from <scp>KEYNOTE... nork Javier Cortés, Eric P. Winer, O. N. Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K. Pruitt, Kenneth Emancipator

    Argitaratua 2024
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

    Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy... nork Paolo A. Ascierto, Hao Tang, Sonia Dolfi, Marta Nyakas, Inge Marie Svane, Eva Muñoz‐Couselo, Jean‐Jacques Grob, Carlos Gomez‐Roca, Vanna Chiarion‐Sileni, Katriina Peltola, James Larkin, Ignacio Melero, Margaret K. Callahan, Reinhard Dummer, Patrick Djidel, Deepti Warad, Diane Reusser-Wolf, Evan J. Lipson, Charlie Garnett‐Benson

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

    Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies nork Azad Saei, Marta Palafox, Touati Benoukraf, Nishi Kumari, Patrick Jaynes, Prasanna Vasudevan Iyengar, Eva Muñoz‐Couselo, Paolo Nucíforo, Javier Cortés, Christopher Nötzel, Nesaretnam Barr Kumarakulasinghe, John Lalith Charles Richard, Zul Fazreen Bin Adam Isa, Brendan Pang, Marta Guzmán, Siqin Zhou, Henry Yang, Wai Leong Tam, Violeta Serra, Pieter J.A. Eichhorn

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

    Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics nork Maria Lozano-Rabella, Andrea García-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Roc Farriol-Duran, Juan Martín-Liberal, Maria Ochoa de Olza, Ignacio Matos, Jared J. Gartner, Michael Ghosh, Francesc Canals, August Vidal, Josep M. Piulats, Xavier Matías‐Guiu, Irene Braña, Eva Muñoz‐Couselo, Elena Garralda, Andreas Schlösser, Alena Gros

    Argitaratua 2023
    Testu osoa Testu osoa
    Carta
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: